Purpose of review
Mucositis has long been viewed as an unavoidable consequence of high-dose chemotherapy and/or radiation. Management has been directed to supportive care including oral pain control, nutritional support, infection treatment and control of diarrhea. Whereas these interventions have been valuable for clinical management, they have not been collectively directed to molecularly targeted prevention and treatment. This review addresses recent advances regarding mucosal injury in cancer patients, with emphasis on symptom clusters, genetically based tissue susceptibility and risk prediction, imaging technology, and computational biology.
Recent findings
Modeling of symptom clusters in cancer patients continues to mature. Although integration of mucositis into the paradigm is at an early stage, recent studies suggest that important molecular and clinical insights will emerge in this regard. Initial studies of genetic-based tissue risk are also providing a research basis that may lead to clinical risk prediction models. These advances are in part being engineered via new imaging and computational biology technologies, drawing upon literature in nonmucositis systems. Just as the past decade has been hallmarked by linkage of pathobiology with clinical expression of mucosal toxicity, the next decade promises to identify new molecular interactions and risk prediction models based on novel application of the analytic technologies. Summary Recent research has culminated in convergence of molecular pathobiology with models of symptom clusters, genetic-based risk, and imaging and computational biology. The field is poised to further delineate this paradigm, with the goal of development of molecularly targeted drugs and devices for mucositis management. develop new approaches for customized therapies analogous to the approach taken for prevention and control of nausea and emesis. Fortunately, important new linkages are being established in the literature relative to molecular causation that is either unique to the gastrointestinal component, or indicative of potentially common causative pathways with those involved in the oral mucositis trajectory [13,14 ,15,16] .
Keywords
There is only one United States Food and Drug Administration (FDA)-approved drug for oral mucositis prevention. This drug, palifermin [17], was approved for use in patients with hematologic malignancies and who are undergoing high-dose chemotherapy without or with radiation, followed by hematopoietic stem cell rescue. Thus, palifermin is approved for use in an at-risk population, but one that represents a relatively small number of the total patients who might otherwise benefit from such mucositis therapies. There are no FDA-approved molecularly targeted drugs to prevent gastrointestinal mucositis. Oral and gastrointestinal mucositis therefore continues to represent an important unmet clinical need.
Thus, new paradigms are needed to comprehensively address the complex relationships among pathobiologic mechanisms, risk for clinical expression, and response to preventive and treatment interventions. Fortunately, the state-of-the-science has positioned the field to achieve major milestones in this modeling over the next 5-10 years.
Symptom clusters
The importance of the adverse impact of multiple toxicities of cancer therapy on the cancer patient has become increasingly apparent over the past 5 years [18-20,21 ,22]. These observations have led to development of the concept of a 'symptom burden' for a given patient, in which both severity of the symptoms as well as the patient's perception of impact of the symptoms are relevant [19] . In this modeling, the 'whole' is indeed greater than the 'sum of the parts'. Even mild toxicities (e.g. World Health Organization grade 2), when occurring in combination, can produce a constellation of injury that can be highly clinically significant. Such modeling creates important implications for targeting reduction in grade 2 toxicities, in addition to the traditionally targeted moderate-to-severe grade 3 and 4 adverse events.
There are few studies of the role of oral and gastrointestinal mucositis on symptom clusters. Symptom clustering research is a relatively new field, and integration with mucositis modeling is in its early stages. Several important opportunities exist for study, including common molecular pathways; and potential impact of the direct reduction of one toxicity on the patient experience of another toxicity. It will be important to consider key research issues (given below) as defined by Miaskowski et al. [18] .
Genetically based tissue susceptibility and risk prediction
For many decades it has been observed that different oral mucosal anatomic sites vary in their risk for developing clinically significant oral mucositis. For example, high-dose chemotherapy often causes at least moderate Oral mucositis Peterson and Lalla 319
Conceptual considerations:
Refinement of the definition of a symptom cluster. Development of criteria to be used to evaluate the relationship between and among the symptoms that are specified within a cluster. Use of the term 'symptom cluster' to refer to the empiric or de-novo identification of symptom clusters using an appropriate statistical procedure (e.g. factor analysis, cluster analysis). Use of the term 'patient subgroups' (not clusters of patients) to refer to groups of patients with different experiences with a specific symptom cluster that are identified using the appropriate statistical procedure (e.g. cluster analysis, latent profile analysis). Determination of the best approaches to evaluate the underlying molecular mechanisms for symptom clusters. Considerations associated with the empiric or de-novo identification of symptom clusters: Comparison of the various statistical approaches to identify symptom clusters. Comparison of the various methodological approaches to identify symptom clusters. Use of symptom severity scores or symptom distress scores to create symptom clusters. Number and types of symptoms on the symptom inventory. Generic versus disease-specific symptom inventories. Epidemiologic studies to identify symptom clusters de novo.
Studies within and across cancer diagnoses. Studies within and across cancer treatments. Studies within and across stages of disease. Considerations associated with the identification of patient subgroups based on their experiences with a specific symptom cluster: Determination of the criteria to be used to include various symptoms with a specific symptom cluster. Determination of the optimal approaches to measure a specific symptom cluster phenotype to insure the most valid and reliable patient subgroups. Use of symptom intensity, symptom distress, and/or symptom frequency measures to characterize a specific symptom cluster phenotype. Use of a single-item symptom inventory versus a number of symptom-specific questionnaires to characterize a specific symptom cluster phenotype. Determination of the optimal statistical approaches to identify subgroups of patients based on their experiences with a specific symptom cluster. Identification of the optimal methods to determine the phenotypic characteristics of patient subgroups with different experiences with a specific symptom cluster. Identification of the optimal methods to characterize the underlying molecular mechanisms that explain the patient subgroups with different experiences with a specific symptom cluster. Replication studies of patient subgroups with different experiences with a specific symptom cluster. Determination of the most sensitive patient outcomes to distinguish among subgroups of patients based on differences in their experiences with a specific symptom cluster.
mucositis of the buccal mucosa, floor-of-mouth, lateral tongue and soft palate, whereas hard palate and attached gingiva are rarely involved [1]. In addition, the classic modeling of uniform commonality among mechanisms for injury across the alimentary tract mucosa are now being challenged by recently emergent data, including a study by Logan et al. [14 ] . Although the definitive new paradigm is not fully established, these new lines of research are providing insights as to why some chemotherapy regimens are more frequently associated than other regimens with oral and gastrointestinal site-specific mucositis. The recent studies may also offer insight into mechanisms by which specific mucosal sites (e.g. conjunctival mucosa) do not typically develop clinical mucositis, whereas other sites (e.g. buccal mucosa) are often at high risk.
As an example of important recent work in this field, the German 5-FU Toxicity Study Group examined genetic markers for toxicity related to 5-fluorouracil (5-FU) [23] . A significant genetic association between a dihydropyrimidine dehydrogenase (DPD) splice site mutation (DYPDÃ2A) and mucositis was observed. These results are consistent with the fact that DPD has been previously shown to rapidly metabolize the majority of 5-FU that is administered. The mutation resulting in DPD deficiency has been described as the major determinant of 5-FUassociated toxicity [24] .
This line of research links well with previous work by another group that studied thymidylate synthase, an enzyme that synthesizes nucleotides. Elevated thymidylate synthase expression has been associated with enhanced survival among patients receiving 5-FU [25] . Reduced thymidylate synthase expression in normal colonic mucosa prior to 5-FU administration has been associated with higher incidence of diarrhea, stomatitis, dose reduction and treatment discontinuation following infusion with 5-FU [26] . Polymorphisms in the thymidylate synthase gene promoter that encodes thymidylate synthase are also associated with 5-FU toxicity in colorectal cancer patients [27] .
Recent work by van Erp et al. [28 ] has demonstrated that the risk for mucosal inflammation was increased in the presence of G allele in CYP1A1 2455A/G in patients receiving single agent sunitinib. These findings are particularly noteworthy, given the application of geneticbased technology to analyze toxicity associated with a molecularly-targeted cancer therapy. This is a new frontier that warrants further investigation.
This collective modeling is setting the stage for potential identification of degree of relative risk of patients developing oral and/or gastrointestinal mucositis. It provides a cogent basis for envisioning a scenario in which genetic variations will be evaluated prior to the determination of cancer therapy regimen in order to select treatments that will be tolerable as well as effective [29] .
Imaging technology
Imaging technology has principally been utilized as a diagnostic tool to evaluate state of health or disease of mucosa. For example, infrared thermography has demonstrated evidence of increased vascularity in patients with mucositis, although the stage of the lesion (e.g. erythema versus ulceration) may be an important confounder relative to signal detection [30] . Orthogonal polarization spectroscopy has utilized polarized light and real-time video imaging to measure microcirculatory velocity and white blood cell margination in relation to acute inflammation [31] . Laser Raman spectroscopy is based on use of inelastic scattering of monochromatic light and has recently been demonstrated to have unique spectra for various oral mucosal sites [32] . Confocal laser endomicroscopy is a light microscopic technique that permits construction of a three-dimensional image based on visualization of mucosal histology [33] [34] [35] . A recent study of side-stream dark-field video microscopy identified alterations in the oral mucosal microvasculature circulation that could represent an important mechanism of early tissue injury [36] . Narrow band imaging is an optical filter technology that can improve visualization of blood vessels, which could provide additional insight into mucosal-based change secondary to cancer therapy [37, 38] .
A novel application of imaging technology was reported in 2008, in which video-capsule endoscopy was utilized to visualize small intestinal mucosal changes secondary to conditioning chemotherapy in autologous hematopoietic stem cell transplant patients [39] . Mucosal edema, erosion and ulceration were observed. This innovative application of existing imaging technology may well lead to new insights relative to the relationship between tissuebased change and clinical symptoms.
The recent advances in imaging technology, including those described above, will likely further enhance the understanding of tissue-based changes in form and function, and also provide new opportunities for standardized assessment of mucosal injury in the research setting.
Computational biology
Given the molecular complexity of oral and gastrointestinal mucositis, it is becoming increasingly important to develop new computational strategies to identify the critical molecular network hubs and downstream pathways involved in the pathogenesis of mucositis. This type of conceptual framework has been utilized for other biologic systems [40] and is becoming increasingly relevant to mucosal injury research as well. A systems biology approach can represent a powerful tool, if there is a robust population of molecular data with which to conduct the computational modeling. These and related studies are contributing to the foundation on which comprehensive data analysis of patients at low, medium and high risk for oral and/or gastrointestinal injury can be studied. This type of research may lead to new paradigms relative to risk prediction for mucositis in the future.
Conclusion
The evidence base for mucositis caused by cancer therapies continues to escalate in scope and volume. The recent application of state-of-the-science imaging and computational technologies from other research fields to the molecular and clinical study of oral and gastrointestinal mucositis is particularly innovative. On the basis of evolution of clinical and scientific knowledge from other toxicities (e.g. nausea and emesis), it seems probable that the next decade of mucositis research will lead to novel opportunities to predict risk of injury as well as incorporate customized preventive and treatment approaches. These advances could mark a new era for management of mucositis caused by cancer therapies, and thus comprehensively redefine the paradigm of the toxicity that has been observed in cancer patients for over 60 years.
